Efficacy News and Research

RSS
Ketamine use on patients with excited delirium and cocaine intoxication increases intubation rate

Ketamine use on patients with excited delirium and cocaine intoxication increases intubation rate

Large-scale SARS-CoV-2 spike protein mutants analysis identifies subclonal variants indicative of within-host viral diversity

Large-scale SARS-CoV-2 spike protein mutants analysis identifies subclonal variants indicative of within-host viral diversity

Study finds correlation between neutralizing antibody titer and reported vaccine efficacy

Study finds correlation between neutralizing antibody titer and reported vaccine efficacy

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

Greater viral load of SARS-CoV-2 variants of concern increases transmission potential

Greater viral load of SARS-CoV-2 variants of concern increases transmission potential

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants show potential to enhance modern cancer treatments

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

SARS-CoV-2 entry inhibitors show antiviral activity

SARS-CoV-2 entry inhibitors show antiviral activity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.